Thoratec REMATCH Preliminary Data Pumps Up Stock 43% In June
This article was originally published in The Gray Sheet
Executive Summary
Encouraging preliminary data from Thoratec's REMATCH trial for treatment of congestive heart failure with the HeartMate VE left ventricular assist system (LVAS) helped the firm's stock beat ahead 42.7% in June. The issue closed at $15.55 for the month, up $4.65.
You may also be interested in...
BPH Thermotherapy Device Competition Heats Up With TherMatrx Entry
TherMatrx is hoping that the design of its TMx-2000 transurethral microwave thermotherapy system to treat benign prostatic hyperplasia - specifically, the absence of a cooling mechanism - will give it an edge over comparable devices on the market.
Thoratec Expecting Near-Term Completion Of Expanded LVAD Indication Trial
Thoratec anticipates completing enrollment for its HeartMate VE left ventricular assist device (LVAD) clinical trial by the end of July, citing the fact that one of the study's predefined endpoints, 92 patient deaths, has almost been reached.
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.